The restorative surgical option for glaucoma

Canaloplasty is a highly effective surgical treatment for moderate to later stage open-angle glaucoma. Performed using Ellex's iTrack™ surgical system, it's a minimally invasive, efficacious and safe technique that restores the eye’s natural outflow system function to reduce elevated intraocular pressure (IOP).

Related products

Related conditions

Related treatments

Main Image Landing Canaloplasty

Highly effective, minimally invasive

For patients with later stage disease, Canaloplasty performed with the iTrack™ surgical system is a proven and effective solution that means patients avoid the risks and discomfort associated with trabeculectomy.

  • Achieves same reduction in IOP as trabeculectomy but with an improved safety profile1
  • Obviates bleb formation – improving and simplifying postoperative care1
  • Extensive peer review data – safe, efficacious, proven

No permanent hole, no bleb

It’s a non-penetrating surgery that does not require the creation of a permanent hole in the eye that can result in bleb formation, and its deployment doesn't preclude or affect the outcome of any future surgical intervention.

Safe, proven, effective

With over 70,000 procedures performed to date, clinical studies show that Canaloplasty has an excellent safety profile, with minimal post-operative follow-up, faster recovery times, and infrequent intra-operative and post-operative complications.

Precisely restorative

Canaloplasty works by restoring the eye's natural outflow pathways. During the procedure, 360º viscodilation of Schlemm’s canal opens up the ostia of the collector channels and re-establishes outflow. Additionally, the creation of the scleral lake, Descemet’s window and a tensioning suture help to contribute to a sustained reduction in IOP.

Less complications, equal efficacy

By addressing all possible sites of resistance, including potentially occluded collector channels, Canaloplasty delivers post-operative pressures in the range of 12-14 mm Hg, similar to that achieved with trabeculectomy — but with fewer complications and an improved safety profile.1

In a three-year multi-center trial by Lewis et al, canaloplasty achieved significantly lower IOP and dependence on medications. Where patients underwent canaloplasty separate to cataract surgery, mean IOP was reduced by 35% from 23.5 mm Hg to 15.5 mm Hg at 36 months. When performed in conjunction with cataract surgery, the technique resulted in a 42% reduction in mean IOP from 23.5 mm Hg to 13.6 mm Hg, combined with an 80% reduction in medications.2

1. Brüggemann A, Despouy JT, Wegent A, Müller M. Intraindividual comparison of Canaloplasty versus trabeculectomy with mitomycin C in a single-surgeon series. J Glaucoma. 2013;22(7):577-583.

2. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm’s canal using a microcatheter to treat open-angle glaucoma. J Cataract Refract. Surg. 2011(37):682-690.

“Rather than trying to mechanically change or bypass the pathway of aqueous outflow, Canaloplasty acts to restore the natural outflow process by targeting all aspects of the outflow system; that is, the trabecular meshwork, Schlemm’s canal, and the collector channels. This is an important distinction of this procedure — especially considering that it is not always understood where the point of maximum resistance lies. It therefore makes sense to apply a procedure that comprehensively addresses the entire outflow system.”

Contact us

Ellex is the manufacturer of the iTrack Canaloplasty microcatheter for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. It has been approved for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal during the Canaloplasty procedure. Ellex does not accept any responsibility for use of the iTrack Canaloplasty microcatheter outside of these indications.

iTrack™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) # K080067 for the treatment of open-angle glaucoma.

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More